The Pfizer-backed Series C round will see Storm work out an accelerated approval pathway for STC-15 in sarcoma.

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik ® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s ...

Ipsen announced Monday it is voluntarily withdrawing its Tazverik cancer drug from all markets after emerging data showed risks may outweigh benefits due to secondary hematologic malignancies. “While ...

NEW YORK – Ipsen is pulling the EZH2 inhibitor Tazverik (tazemetostat) from the market after weighing the increased rates of secondary blood cancers against treatment benefits. The Paris-based firm on ...

Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, China. Epithelioid hemangioma (EH) of bone is a rare vascular tumor. According to the 2020 World Health ...

MOORHEAD, MN (KVRR) – Community members packed a local pickleball venue to raise money for a West Fargo man who is battling a rare form of cancer for the second time. Brad Lindblad was first diagnosed ...

It's not often that a pathologist gets to make a diagnosis that works for the patient by preventing treatment from occurring. But thanks to a Johns Hopkins Medicine doctor and his newly reported ...

WEDNESDAY, Nov. 19, 2025 (HealthDay News) -- The prevalence of primary epithelioid sarcoma (PES) is 0.49 per 100,000 in the United States and is highest among t ...

Epithelioid sarcoma (ES) is a rare soft tissue malignancy of uncertain differentiation that can arise in various anatomical locations; however, its occurrence in the mediastinum is exceptionally ...